Elevated Serum Uric Acid Concentrations Independently Predict Cardiovascular Mortality in Type 2 Diabetic Patients by Zoppini, Giacomo et al.
Elevated Serum Uric Acid Concentrations
Independently Predict Cardiovascular
Mortality in Type 2 Diabetic Patients
GIACOMO ZOPPINI, MD
GIOVANNI TARGHER, MD
CARLO NEGRI, MD
VINCENZO STOICO, MD
FABRIZIA PERRONE, MD
MICHELE MUGGEO, MD
ENZO BONORA, MD
OBJECTIVE — There is limited information on whether increased serum uric acid levels are
independently associated with cardiovascular mortality in type 2 diabetes. We assessed the
predictive role of serum uric acid levels on all-cause and cardiovascular mortality in a large
cohort of type 2 diabetic individuals.
RESEARCH DESIGN AND METHODS — The cohort included 2,726 type 2 diabetic
outpatients, who were followed for a mean period of 4.7 years. The independent association of
serum uric acid levels with all-cause and cardiovascular mortality was assessed by Cox propor-
tional hazards models and adjusted for conventional risk factors and several potential
confounders.
RESULTS — During follow-up, 329 (12.1%) patients died, 44.1% (n  145) of whom from
cardiovascular causes. In univariate analysis, higher serum uric acid levels were signiﬁcantly
associated with increased risk of all-cause (hazard ratio 19 [95% CI 1.12–1.27], P  0.001) and
cardiovascular (1.25 [1.16–1.34], P  0.001) mortality. After adjustment for age, sex, BMI,
smoking, hypertension, dyslipidemia, diabetes duration, A1C, medication use (allopurinol or
hypoglycemic, antihypertensive, lipid-lowering, and antiplatelet drugs), estimated glomerular
ﬁltration rate, and albuminuria, the association of serum uric acid with cardiovascular mortality
remained statistically signiﬁcant (1.27 [1.01–1.61], P  0.046), whereas the association of
serum uric acid with all-cause mortality did not.
CONCLUSIONS — Higher serum uric acid levels are associated with increased risk of car-
diovascular mortality in type 2 diabetic patients, independent of several potential confounders,
including renal function measures.
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C
ardiovascular disease (CVD) repre-
sents the most common cause of
morbidity and mortality in the type
2 diabetic population (1,2). Several bio-
chemical parameters have been associ-
atedwithincreasedriskforCVDintype2
diabetes (3–5). Increased levels of serum
uric acid are quite common in type 2 di-
abetic patients (6), and they might repre-
sentanadditionalCVDriskfactorinthese
patients (7,8).
Whereas several prospective studies
have consistently demonstrated that ele-
vated serum uric acid levels are an inde-
pendent risk factor for CVD mortality in
the general population (9–13), there is
currentlyapaucityofavailabledataonthe
association between serum uric acid lev-
els and CVD mortality in the type 2 dia-
betic population. In a small retrospective
study of 535 type 2 diabetic patients, it
wasfoundthathigherserumuricacidlev-
els were signiﬁcantly associated with an
increased risk of all-cause mortality (14).
However, no information was available
on speciﬁc causes of mortality in such
studies, and no adjustment was made for
important risk factors, such as diabetes
duration and albuminuria. In another
small study of 581 elderly type 2 diabetic
patients, it was found that higher serum
uric acid levels independently predicted
cardiovascular mortality, but the authors
did not adjust for glycemic control, use of
medications, and albuminuria (15). In
this respect, it is important to emphasize
that the progressive decline in kidney
function, which frequently occurs with
aging and the course of type 2 diabetes, is
also generally paralleled by progressive
increases in serum uric acid levels (16).
Thus, the presence of renal dysfunction,
as assessed by glomerular ﬁltration rate
and albuminuria, should be always taken
into account when the association of se-
rum uric acid levels with mortality is ex-
plored, especially in the type 2 diabetic
population.
The aim of this prospective study was
toinvestigatewhetheranassociationdoes
exist between serum uric acid concentra-
tions and all-cause and cardiovascular
mortality in a large cohort of type 2 dia-
betic individuals, independent of several
baseline confounding factors, including
markers of kidney function.
RESEARCH DESIGN AND
METHODS— The study was per-
formed within the framework of the Ve-
rona Diabetes Study, an observational
longitudinal study on chronic complica-
tions in type 2 diabetic outpatients at-
tending the Diabetes Clinic at the
University Hospital of Verona (2,17,18).
For this study, we initially considered all
type2diabeticoutpatients,whoregularly
attended our clinic during years 2000–
2002 (n  3,924). Type 2 diabetes was
established when diagnosis was made at
age 35 years, irrespective of treatment,
or when the disease was treated with diet
or oral hypoglycemic agents, irrespective
of age at diagnosis. After excluding 1) pa-
tients (n  881, 22.5% of total), who had
a history of malignancy, severe chronic
obstructive pulmonary disease, end-stage
renal disease, or CVD (deﬁned as angina,
myocardial infarction, coronary or pe-
ripheral revascularization procedures,
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total), who had missing data for albumin-
uria, serum uric acid, and creatinine con-
centrations,2,845type2diabeticpatients
(72.5% of total) were included in the
study. The local ethics committee ap-
proved the study protocol. All partici-
pants gave their informed consent.
BMI was calculated by dividing
weight in kilograms by the square of
heightinmeters.Bloodpressurewasmea-
sured with a standard mercury manome-
ter. Information on diabetes duration,
previous diseases, current use of medica-
tions, and smoking status was obtained
for all patients by interviews during med-
ical visits.
In all patients, venous blood was
withdrawn in the morning after an over-
night fast for a standard biochemical
workup. Serum uric acid, lipids, creati-
nine, and other biochemical blood mea-
surements were determined by automatic
colorimetric methods (DAX 96; Bayer Di-
agnostics, Milan, Italy). LDL cholesterol
was calculated by the Friedewald for-
mula. A1C was measured by a high-
performance liquid chromatography
analyzer (Diamat; Bio-Rad, Milan, Italy),
and the upper limit of normality was
5.8%. Glomerular ﬁltration rate (GFR)
was estimated from the abbreviated Mod-
iﬁcation of Diet in Renal Disease (MDRD)
formula (19) as follows: estimated GFR
(eGFR)  186.3  (serum creati-
nine
1.154)  (age
0.203)  1.212 (if
black) or  0.742 (if female). Urinary al-
bumin was measured by an immunon-
ephelometric method on an early
morning spot sample, collected three
times, and was expressed as the albumin-
to-creatinine ratio. Microalbuminuria
andmacroalbuminuriaweredeﬁnedasan
albumin-to-creatinine ratio 2.5 and
30 mg/mmol for men and 3.5 and
30 mg/mmol for women, respectively
(20).
Hypertension was deﬁned as systolic
blood pressure 140 mmHg and/or dia-
stolic blood pressure 90 mmHg or
current use of any treatment with antihy-
pertensive medications. Detailed infor-
mation regarding speciﬁc classes of
antihypertensive drugs was not currently
available in our informatic database.
Atherogenic dyslipidemia was diagnosed
when plasma triglycerides were 1.7
mmol/l and/or HDL cholesterol was
1.04mmol/lorwhenpatientsweretak-
ing lipid-lowering agents. Hyperuricemia
was diagnosed when the serum uric acid
concentration was 416 mol/l in men
and 386 mol/l in women, respec-
tively, or when patients were taking
allopurinol.
Vital status was ascertained by exam-
iningtheelectronicdatabasesoftheSocial
Health Unit of the Veneto Region, which
include all records of mortality occurring
within the Veneto Region as well as indi-
vidual causes of death. The ascertainment
at the end of follow-up (mean  SD du-
ration 4.7  0.8 years, range 1–5 years)
was 96% complete. Subjects (n  119)
who moved and could not be traced were
classiﬁed as being lost during the fol-
low-up and then were excluded from
analysis.
Participants who attended the fol-
low-up examinations (n  2,726) were
essentially similar to those of the initial
cohort (n  3,924), to those who had
missing data for albuminuria, serum uric
acid, and creatinine concentrations (n 
198), and to those who did not attend the
follow-up examinations (n  119) in
terms of demographic variables, glycemic
control, and diabetes duration.
Thecausesofdeathwereidentiﬁedby
reviewing death certiﬁcates, which were
available in 100% of cases. Death certiﬁ-
cates were coded by trained nosologists
usingtheICD-9.Thedeathwasattributed
to cardiovascular causes when ICD-9
codes were 390–459.
Statistical analysis
Subjects were stratiﬁed into tertiles of se-
rumuricacid,whichwerecalculatedsep-
arately in men (i.e., lower tertile 270,
middle tertile 270–330, and upper tertile
330 mol/l) and women (230, 230–
300, and 300 mol/l, respectively).
Skewed variables were logarithmically
transformed to improve normality before
analyses. ANOVA and the 
2 test with
Yates’s correction for continuity (for cate-
gorical variables) were used to compare
clinical and biochemical features across
tertiles of serum uric acid. Kaplan-Meier
analysis was used to determine univariate
survival according to sex-speciﬁc serum
uric acid tertiles, and the signiﬁcance was
calculated by the log-rank test. The Cox
proportional hazards model was used to
assess the independent association of se-
rumuricacidlevels(includedasacontin-
uous variable) with all-cause and
cardiovascular mortality. Three multivar-
iate regression models were performed.
The ﬁrst one included serum uric acid
(micromoles per liter), age (years), sex
(male vs. female), BMI (kilograms per
square meter), A1C (percentage), diabe-
tes duration (years), smoking status (cur-
rent vs. former/never), hypertension (yes/
no; see deﬁnition above), atherogenic
dyslipidemia (yes/no; see deﬁnition
above), LDL cholesterol (millimoles per
liter), and current use of medications (al-
lopurinol, antiplatelet, and hypoglycemic
drugs) (yes/no). A second multivariate re-
gression model also included eGFR (mil-
liliters per minute per 1.73 m
2), and a
third model also included albuminuria
(categorized as normal, microalbumin-
uria, and macroalbuminuria). In supple-
mentary multivariate regression analyses,
serum uric acid levels were replaced by
hyperuricemia included as a categorical
measure. The covariates included in the
threemultivariateregressionmodelswere
chosenaspotentialconfoundersbasedon
their biological plausibility or statistical
association with mortality in univariate
analysis. Forced entry models were used,
i.e.,allcovariatesweresimultaneouslyin-
cluded in the regression models. Results
are presented as hazard ratios (HRs) with
95% CIs, and statistical signiﬁcance was
evaluatedbythelikelihoodratiotest.HRs
for continuous variables were computed
for 1-SD change. Statistical analyses
were performed with SPSS (version
14.0). P  0.05 was considered statisti-
cally signiﬁcant.
RESULTS— Hyperuricemia was
present in 16.1% (n  438) of the whole
cohort of participants. Among them, 225
type 2 diabetic patients were taking allo-
purinol. The baseline clinical and bio-
chemical characteristics of participants
grouped by sex-speciﬁc serum uric acid
tertiles are shown in Table 1. Compared
with those in the lower tertile, patients in
the upper tertile of serum uric acid levels
were more likely to be male, older, over-
weight/obese, and hypertensive and to be
taking oral hypoglycemic, antihyperten-
sive, and antiplatelet agents. They also
had a shorter duration of diabetes and
were less likely to be smokers and treated
with insulin. Patients in the upper tertile
of serum uric acid levels also had higher
values of LDL cholesterol, triglycerides,
and albuminuria and lower values of
A1C, HDL cholesterol, and eGFR.
During the follow-up period, 329
(12.1%) participants died, 145 (44.1%)
of whom from cardiovascular causes.
Numbers of deaths and cumulative inci-
dence rates of all-cause mortality were 81
(9.8%), 103 (10.7%), and 145 (15.4%)
across tertiles of serum uric acid levels,
respectively (P  0.001 for trend). Ac-
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mulativeincidenceratesofCVDmortality
were 28 (3.4%), 43 (4.5%), and 74
(7.9%), respectively (P  0.001 for
trend).
Figure 1 shows the results of the
Kaplan-Meier survival analysis for CVD
mortality. Patients in the third tertile of
serum uric acid levels had a remarkably
lower survival probability than those in
the ﬁrst and second tertiles (P  0.001 by
the log-rank test).
In univariate Cox regression analysis,
higher serum uric acid levels were signif-
icantly associated with an increased risk
of all-cause (HR 1.19 [95% CI 1.12–
1.27], P  0.001) and CVD mortality
(1.25[1.16–1.34],P0.001).Theinde-
pendent association of serum uric acid
levels with mortality was tested by several
multivariate regression models. Higher
serum uric acid levels were associated
with increased risk of CVD mortality,
with a 	20% increase in the CVD risk for
each SD (95 mol/l) increment, indepen-
dentofage,sex,conventionalriskfactors,
current use of medications, and other po-
tential confounders (Table 2, model 1).
When this association was also adjusted
for eGFR (model 2) or for both eGFR and
albuminuria(model3),higherserumuric
acid levels remained a signiﬁcant positive
predictor of CVD mortality. Almost iden-
tical results were found when allopurinol
users (n  225) were excluded from sta-
tistical analysis (data not shown). The
possible presence of a statistical interac-
tion between serum uric acid levels and
eGFRwastestedbyintroducingtheprod-
uct term of these two variables in Cox re-
gression models. In the fully adjusted
regression model, this interaction term
wasnotsigniﬁcantlyassociatedwithCVD
mortality (adjusted HR 0.88 [0.71–1.05],
P  0.15).
Higher serum uric acid levels were
also associated with increased risk of all-
cause mortality independent of age, sex,
conventional risk factors, glycemic con-
trol,medications,andeGFR(model1:ad-
justed HR 1.14 [95% CI 1.06–1.23], P 
0.001; model 2: 1.12 [1.01–1.25], P 
0.043). However, the signiﬁcant associa-
tion between serum uric acid and all-
cause mortality disappeared after further
adjustment for albuminuria (model 3:
1.08 [0.96–1.27], P  0.374). Interest-
ingly, the lack of an independent associa-
tion between serum uric acid levels and
all-cause mortality was also conﬁrmed by
a Cox multivariate regression model in
which only age, sex, eGFR, and albumin-
uria were included as covariates (1.06
[0.91–1.24], P  0.42). Almost identical
results were also found after patients who
died of cardiovascular diseases were ex-
cluded. Also in this case, the signiﬁcant
association between serum uric acid lev-
els and non-CVD mortality disappeared
after adjustment for age, sex, eGFR, and
albuminuria (0.93 [0.74–1.16], P 
0.51).
CONCLUSIONS — To our knowl-
edge, this is the largest prospective study
with the speciﬁc aim of assessing the as-
sociation of serum uric acid levels with
all-cause and CVD mortality in a type 2
diabetic population. Notably, in the
present study the association between se-
rumuricacidlevelsandmortalitywasad-
justed for several baseline confounding
factors, such as age, sex, adiposity, smok-
ing, hypertension, dyslipidemia, diabetes
duration, glycemic control, medication
use, and kidney function measures.
The major ﬁnding of this study is that
higher levels of serum uric acid are inde-
pendently associated with increased CVD
mortality but not all-cause mortality. The
failure to ﬁnd an independent association
between serum uric acid levels and all-
cause mortality after additional adjust-
ment for albuminuria is not readily
explainable, but it is unlikely that this is
due to a reduced statistical power to de-
tect an association. Indeed, the lack of an
independent association between serum
uric acid levels and all-cause mortality
was also conﬁrmed by a Cox regression
modelinwhichfewercovariates(i.e.,age,
sex, eGFR, and albuminuria) were in-
cluded.Anotherinterestingﬁndingofour
study is that higher serum uric acid levels
arealsoindependentlyassociatedwithin-
creased CVD mortality in patients with
kidney dysfunction.
Whether increased serum uric acid
concentrations are just a risk indicator or
a causative risk factor of CVD (21,22)
Table1—Baselineclinicalandbiochemicalcharacteristicsoftype2diabeticpatientsstratiﬁed
into sex-speciﬁc tertiles of serum uric acid levels
Tertile I Tertile II Tertile III P
Sex (male/female) 475/349 482/479 550/391 0.001
Age (years) 67  10 67  10 68  9 0.006
Current smokers 26.1 20.7 23.2 0.009
Diabetes duration (years) 16  91 5  91 5  9 0.004
BMI (kg/m
2) 27.1  4.4 28.3  4.5 29.4  4.8 0.001
Hypertension 80 85.6 90.8 0.001
A1C (%) 7.7  1.5 7.5  1.5 7.4  1.4 0.001
LDL cholesterol (mmol/l) 3.3  0.9 3.4  0.9 3.4  0.9 0.016
HDL cholesterol (mmol/l) 1.5  0.4 1.4  0.4 1.3  0.4 0.001
Triglycerides (mmol/l) 1.4  1.0 1.6  1.0 1.8  1.0 0.001
eGFR (ml/min per 1.73 m
2) 80.5  18.7 74.7  17.7 66.8  18.7 0.001
Microalbuminuria 18.3 20.0 23.3 0.025
Macroalbuminuria 4.3 5.1 6.9 0.025
Serum uric acid (mol/l) 207  36 280  26 388  91 ND
Oral hypoglycemic drugs 54.2 60.6 57.2 0.004
Insulin therapy 37.0 30.0 31.0 0.004
Antihypertensive drugs 64.9 73.7 82.0 0.001
Lipid-lowering drugs 44.8 46.1 47.7 0.464
Antiplatelet drugs 39.1 41.3 46.7 0.004
Allopurinol therapy 4.4 7.8 12.1 0.001
DataareexpressedasmeansSD,percent,orproportions.Cohortsize,n2,726.Pvaluesrefertoone-way
ANOVA or the 
2 test (for categorical variables). ND, not determined.
Figure 1—Kaplan-Meier curves of cardiovas-
cular mortality in 2,726 type 2 diabetic pa-
tients stratiﬁed by sex-speciﬁc tertiles of serum
uric acid levels. Statistical signiﬁcance was es-
timated by the log-rank test (P  0.001 for the
third tertile vs. the other two tertiles).
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ical studies such as ours. Higher serum
uric acid levels may indirectly contribute
to the increased CVD risk through a close
association with established risk factors,
such as older age, hypertension, dyslipi-
demia, poor glycemic control, and
chronic kidney disease. However, be-
cause in our study higher serum uric acid
levels were associated with increased risk
of CVD mortality independent of a broad
spectrum of known risk factors, it is con-
ceivablethatserumuricacidmightconfer
an excess risk over and above the risk ex-
pected as a result of the underlying estab-
lished risk factors.
Recognitionoftheunderlyingbiolog-
icalmechanism(s)linkingserumuricacid
levels with CVD mortality is beyond the
speciﬁc scope of this study. However,
some putative biological mechanisms
may be mentioned. Experimental studies
in animals have suggested that elevated
serum uric acid levels may increase the
expression of chemokines and cytokines
in the vasculature, activate the renin-
angiotensinsystem,andincreasesystemic
C-reactive protein expression (23). Ac-
cordingly, treatment with allopurinol
mayimproveendothelialfunctioninsub-
jects with hyperuricemia (24) and in hy-
pertensive type 2 diabetic patients with
normal serum uric acid levels (25). How-
ever, additional studies are needed to
elucidatetheunderlyingmolecularmech-
anisms before causality can be ﬁrmly
established.
Overall, these ﬁndings might have
potential clinical implications. Our re-
sults support the implication that the
measurement of serum uric acid concen-
trations in individuals with type 2 diabe-
tesmaybehelpfulinCVDriskprediction.
If results of future studies support the
conclusion that increased levels of serum
uric acid may play a direct role in the
pathophysiology of CVD, hyperuricemia
will be another target for the treatment of
type 2 diabetes.
The present study has several impor-
tant limitations that merit comment.
These include a single baseline measure-
mentofthevariablesofinterest,apossible
selection bias of excluding nearly 5% of
the patients who had incomplete bio-
chemical data for analysis, a possible im-
pact of losses to follow-up, an inability
to adjust for certain speciﬁc antihyper-
tensive agents (e.g., ACE inhibitors, an-
giotensin receptor blockers, or loop
diuretics),andanissueofmultipletesting
with a propensity for false-positive asso-
ciations. In addition, we used eGFR in-
steadofadirectlymeasuredGFRtodeﬁne
chronickidneydisease.Nonetheless,cur-
rent GFR estimates facilitate the detec-
tion, evaluation, and management of
chronickidneydisease,andmanyorgani-
zations recommend the use of prediction
equations for the evaluation of kidney
function in large epidemiological studies
and in clinical practice (19,20). Finally,
whether these observations can also be
extendedtonon-Caucasianethnicgroups
remains to be determined.
Notwithstanding these limitations,
ourstudyhasseveralimportantstrengths,
including its prospective design, the large
number of participants, and the ability to
adjust for a wide range of known risk fac-
tors and potential confounders. In addi-
tion, our patients were free of diagnosed
CVD, malignancy, and kidney failure; the
evaluation of patients with such compli-
cations would almost certainly have con-
founded interpretation of the data.
Insummary,ourﬁndingssuggestthat
higher serum uric acid levels are associ-
ated with increased risk of CVD mortality
in type 2 diabetic individuals, indepen-
dent of conventional risk factors, diabe-
tes-related variables, medication use, and
renal function measures.
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